vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.1倍（$173.1M vs $156.4M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs 3.6%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 10.8%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
BCRX vs PLPC — 直观对比
营收规模更大
PLPC
是对方的1.1倍
$156.4M
营收增速更快
BCRX
高出3.9%
3.6%
两年增速更快
BCRX
近两年复合增速
10.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $173.1M |
| 净利润 | — | $8.4M |
| 毛利率 | — | 29.8% |
| 营业利润率 | 13.6% | 6.8% |
| 净利率 | — | 4.9% |
| 营收同比 | 7.5% | 3.6% |
| 净利润同比 | — | -19.3% |
| 每股收益（稀释后） | $0.00 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXPLPC
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $173.1M | ||
| Q3 25 | $159.4M | $178.1M | ||
| Q2 25 | $163.4M | $169.6M | ||
| Q1 25 | $145.5M | $148.5M | ||
| Q4 24 | $131.5M | $167.1M | ||
| Q3 24 | $117.1M | $147.0M | ||
| Q2 24 | $109.3M | $138.7M |
净利润BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $8.4M | ||
| Q3 25 | $12.9M | $2.6M | ||
| Q2 25 | $5.1M | $12.7M | ||
| Q1 25 | $32.0K | $11.5M | ||
| Q4 24 | $-26.8M | $10.5M | ||
| Q3 24 | $-14.0M | $7.7M | ||
| Q2 24 | $-12.7M | $9.4M |
毛利率BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 29.8% | ||
| Q3 25 | 98.6% | 29.7% | ||
| Q2 25 | 98.3% | 32.7% | ||
| Q1 25 | 96.9% | 32.8% | ||
| Q4 24 | 95.4% | 33.3% | ||
| Q3 24 | 97.3% | 31.1% | ||
| Q2 24 | 98.4% | 31.9% |
营业利润率BCRXPLPC
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 6.8% | ||
| Q3 25 | 18.6% | 7.4% | ||
| Q2 25 | 18.2% | 10.1% | ||
| Q1 25 | 14.6% | 8.8% | ||
| Q4 24 | -3.4% | 10.5% | ||
| Q3 24 | 6.6% | 7.1% | ||
| Q2 24 | 8.0% | 8.1% |
净利率BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 4.9% | ||
| Q3 25 | 8.1% | 1.5% | ||
| Q2 25 | 3.1% | 7.5% | ||
| Q1 25 | 0.0% | 7.8% | ||
| Q4 24 | -20.4% | 6.3% | ||
| Q3 24 | -12.0% | 5.2% | ||
| Q2 24 | -11.6% | 6.8% |
每股收益（稀释后）BCRXPLPC
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $1.72 | ||
| Q3 25 | $0.06 | $0.53 | ||
| Q2 25 | $0.02 | $2.56 | ||
| Q1 25 | $0.00 | $2.33 | ||
| Q4 24 | $-0.13 | $2.13 | ||
| Q3 24 | $-0.07 | $1.54 | ||
| Q2 24 | $-0.06 | $1.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | — | $475.5M |
| 总资产 | $465.1M | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资BCRXPLPC
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | — | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | — |
总债务BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M |
股东权益BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $475.5M | ||
| Q3 25 | $-387.9M | $466.3M | ||
| Q2 25 | $-421.6M | $460.7M | ||
| Q1 25 | $-451.9M | $435.8M | ||
| Q4 24 | $-475.9M | $422.3M | ||
| Q3 24 | $-468.6M | $429.0M | ||
| Q2 24 | $-475.6M | $416.2M |
总资产BCRXPLPC
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $653.6M | ||
| Q3 25 | $446.4M | $644.6M | ||
| Q2 25 | $457.2M | $631.5M | ||
| Q1 25 | $480.0M | $592.5M | ||
| Q4 24 | $490.4M | $573.9M | ||
| Q3 24 | $491.3M | $592.0M | ||
| Q2 24 | $472.4M | $572.6M |
负债/权益比BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $21.9M |
| 自由现金流经营现金流 - 资本支出 | — | $11.8M |
| 自由现金流率自由现金流/营收 | — | 6.8% |
| 资本支出强度资本支出/营收 | — | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | — | $33.3M |
8季度趋势，按日历期对齐
经营现金流BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $21.9M | ||
| Q3 25 | $41.6M | $18.9M | ||
| Q2 25 | $41.3M | $26.9M | ||
| Q1 25 | $-27.5M | $5.7M | ||
| Q4 24 | $-5.2M | $24.1M | ||
| Q3 24 | $8.2M | $9.4M | ||
| Q2 24 | $-1.4M | $28.3M |
自由现金流BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $11.8M | ||
| Q3 25 | $40.3M | $8.3M | ||
| Q2 25 | $41.1M | $18.6M | ||
| Q1 25 | $-27.7M | $-5.3M | ||
| Q4 24 | $-5.9M | $20.6M | ||
| Q3 24 | $8.2M | $5.8M | ||
| Q2 24 | $-1.5M | $24.6M |
自由现金流率BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 6.8% | ||
| Q3 25 | 25.3% | 4.7% | ||
| Q2 25 | 25.2% | 10.9% | ||
| Q1 25 | -19.0% | -3.6% | ||
| Q4 24 | -4.5% | 12.3% | ||
| Q3 24 | 7.0% | 3.9% | ||
| Q2 24 | -1.4% | 17.7% |
资本支出强度BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 5.9% | ||
| Q3 25 | 0.8% | 6.0% | ||
| Q2 25 | 0.1% | 4.9% | ||
| Q1 25 | 0.1% | 7.4% | ||
| Q4 24 | 0.5% | 2.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.1% | 2.7% |
现金转化率BCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 2.60× | ||
| Q3 25 | 3.23× | 7.21× | ||
| Q2 25 | 8.12× | 2.12× | ||
| Q1 25 | -859.91× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
PLPC
暂无分部数据
